Your browser doesn't support javascript.
loading
Prevalence and Outcomes for Heavily Treatment-Experienced Individuals Living With Human Immunodeficiency Virus in a European Cohort.
Pelchen-Matthews, Annegret; Borges, Álvaro H; Reekie, Joanne; Rasmussen, Line D; Wiese, Lothar; Weber, Jonathan; Pradier, Christian; Degen, Olaf; Paredes, Roger; Tau, Luba; Flamholc, Leo; Gottfredsson, Magnus; Kowalska, Justyna; Jablonowska, Elzbieta; Mozer-Lisewska, Iwona; Radoi, Roxana; Vasylyev, Marta; Kuznetsova, Anastasiia; Begovac, Josip; Svedhem, Veronica; Clark, Andrew; Cozzi-Lepri, Alessandro.
Afiliación
  • Pelchen-Matthews A; Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, United Kingdom.
  • Borges ÁH; Department of Infectious Diseases Immunology, Statens Serum Institut, Copenhagen, Denmark.
  • Reekie J; Department of Infectious Diseases, Centre for Health and Infectious Disease Research, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Rasmussen LD; Department of Infectious Diseases, Odense University Hospital, Odense, Denmark.
  • Wiese L; Sjællands Universitetshospital, Roskilde, Denmark.
  • Weber J; St. Mary's Hospital, London, United Kingdom.
  • Pradier C; CHU Nice Hopital de l' Archet 1, Nice, France.
  • Degen O; University Clinic Hamburg Eppendorf, Hamburg, Germany.
  • Paredes R; Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
  • Tau L; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Flamholc L; Skåne University Hospital, Malmö, Sweden.
  • Gottfredsson M; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
  • Kowalska J; Medical University of Warsaw, Warsaw, Poland.
  • Jablonowska E; Clinic of Infectious Diseases and Hepatology, Medical University of Lodz, Lodz, Poland.
  • Mozer-Lisewska I; Poznan University of Medical Sciences, Poznan, Poland.
  • Radoi R; Victor Babes Clinical Hospital for Infectious and Tropical Diseases, Bucharest, Romania.
  • Vasylyev M; HIV Unit, Lviv Regional Public Health Center, Lviv, Ukraine.
  • Kuznetsova A; Kharkov State Medical University, Kharkov, Ukraine.
  • Begovac J; University Hospital for Infectious Diseases Dr. Fran Mihaljevic, Zagreb, Croatia.
  • Svedhem V; Infectious Diseases Department, Karolinska University Hospital, Infectious Diseases Department, Stockholm, Sweden ; and.
  • Clark A; ViiV Healthcare, London, United Kingdom .
  • Cozzi-Lepri A; Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, United Kingdom.
J Acquir Immune Defic Syndr ; 87(2): 806-817, 2021 06 01.
Article en En | MEDLINE | ID: mdl-33587506
BACKGROUND: Although antiretroviral treatments have improved survival of persons living with HIV, their long-term use may limit available drug options. We estimated the prevalence of heavily treatment-experienced (HTE) status and the potential clinical consequences of becoming HTE. SETTING: EuroSIDA, a European multicenter prospective cohort study. METHODS: A composite definition for HTE was developed, based on estimates of antiretroviral resistance and prior exposure to specific antiretroviral regimens. Risks of progressing to clinical outcomes were assessed by Poisson regression, comparing every HTE individual with 3 randomly selected controls who never became HTE. RESULTS: Of 15,570 individuals under follow-up in 2010-2016, 1617 (10.4%, 95% CI: 9.9% to 10.9%) were classified as HTE. 1093 individuals became HTE during prospective follow-up (HTE incidence rate 1.76, CI: 1.66 to 1.87 per 100 person-years of follow-up). The number of HTE individuals was highest in West/Central Europe (636/4019 persons, 15.7%) and lowest in East Europe (26/2279 persons, 1.1%). Although most HTE individuals maintained controlled viral loads (<400 copies/mL), many had low CD4 counts (≤350 cells/µL). After controlling for age, immunological parameters and pre-existing comorbidities, HTE status was not associated with the risk of new AIDS (adjusted incidence rate ratio, aIRR 1.44, CI: 0.86 to 2.40, P = 0.16) or non-AIDS clinical events (aIRR 0.96, CI: 0.74 to 1.25, P = 0.77). CONCLUSIONS: HTE prevalence increased with time. After adjusting for key confounding factors, there was no evidence for an increased risk of new AIDS or non-AIDS clinical events in HTE. Additional therapeutic options and effective management of comorbidities remain important to reduce clinical complications in HTE individuals.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndrome de Inmunodeficiencia Adquirida / Fármacos Anti-VIH / Terapia Antirretroviral Altamente Activa Tipo de estudio: Clinical_trials / Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: J Acquir Immune Defic Syndr Asunto de la revista: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndrome de Inmunodeficiencia Adquirida / Fármacos Anti-VIH / Terapia Antirretroviral Altamente Activa Tipo de estudio: Clinical_trials / Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: J Acquir Immune Defic Syndr Asunto de la revista: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Estados Unidos